Joincare Pharmaceutical Group placed 6,382,500 GDRs at an offer price of USD 14.42 per GDR, with one (1) GDR representing an interest in ten (10) A-shares of the company. The A-shares of the company are listed on the Shanghai Stock Exchange. Joincare Pharmaceutical Group raised gross proceeds of approximately USD 92.0 million from the GDRs offering.
Joincare Pharmaceutical Group is an innovation-driven integrated pharmaceutical company which combines pharmaceutical R&D, manufacturing and commercialization, as well as a pioneer and leader in the field of complex formulation in China. Its mission is to diligently make high-quality and innovative drugs.
Mr. Zhu Baoguo, Chairman Joincare Pharmaceutical Group, says: “We are delighted with the successful GDR offering, and we would like to extend our gratitude to our investors for their full confidence in and recognition of the company. This is an important milestone of Joincare’s internationalization.”
Jos Dijsselhof, CEO SIX, emphasizes: “We are delighted to welcome Joincare Pharmaceutical Group to our exchange today. This GDR listing marks the sixth this year already. In total, the six GDR offerings have raised an aggregated amount of approximately USD 1.9 billion, which proves the success of the GDR segment offering by SIX.“
More information about the company is available here.
Please do not hesitate to contact Julian Chan.
About SIX
SIX serves the Swiss and Spanish financial centers and a broad international client base, offering stable and efficient infrastructure services. SIX operates stock exchanges and provides services in securities, financial information as well as the payments business. The company is owned by its users (about 120 financial institutions). With over 4,400 employees and a presence in 20 countries, SIX generated operating income of CHF 1.6 billion and EBITDA of CHF 443.7 million in 2024.
www.six-group.com